Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
News|Articles|January 1, 2006
Retrospective analysis demontrates that switching statins hinders treatment compliance, persistence
Patients who have switched statins should receive special care as they are substantially less likely to be compliant and remain on the treatment long enough to obtain its full benefits, researchers reported in the American Journal of Managed Care.
Advertisement
Advertisement
Related to this article
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
Employers Health’s Alexis Sova says employers excluding GLP-1s now lean on weight management programs and direct-to-employer deals, not a hard cutoff.
Chad Hatfield, Pharm.D., MHA, BCPS, of UC Davis Health, discusses the system's pharmacy shared service center, embedded pharmacists and 340B rebate readiness.
Blood tests reveal early, widespread inflammation in hidradenitis suppurativa, linking biomarkers to disease severity, quality of life, smoking, and potential cardiovascular risk.
UCLA research suggests that GLP-1 therapies may protect bone health in Type 2 diabetes patients.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Dupixent shows staying power in adolescents and children with atopic dermatitis
2
National Alliance names interim head after arrest of its president
3
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
4
Using TMS to address the cognitive symptoms of schizophrenia
5